Cognitive dispersion profiles and prediction of cognitive change in early-onset dementias: Results from LEADS.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hammers Dustin B, Foster Elodie, Eloyan Ani, Thangarajah Maryanne, Taurone Alexander, Touroutoglou Alexandra, La Joie Renaud, Beckett Laurel, Gao Sujuan, Vemuri Prashanthi, Nudelman Kelly N, Kirby Kala, Dage Jeffrey L, Aisen Paul, Atri Alireza, Clark David, Day Gregory S, Duara Ranjan, Graff-Radford Neill R, Grant Ian, Honig Lawrence S, Johnson Erik C B, Jones David T, Masdeu Joseph C, Mendez Mario F, Parand Leila, Womack Kyle, Musiek Erik, Onyike Chiadi U, Riddle Meghan, Rogalski Emily, Salloway Stephen, Sha Sharon J, Turner Raymond Scott, Wingo Thomas S, Wolk David A, Dickerson Bradford C, Rabinovici Gil D, Carrillo Maria C, Apostolova Liana G, LEADS Consortium
Аннотация
METHODS: A total of 309 participants (188 amyloid-positive EOAD, 43 amyloid-negative early-onset dementia [EOnonAD], 78 cognitively normal [CN]) completed neuropsychological testing twice over 12 months. Dispersion-related differences among groups were assessed, as was cognitive dispersion's capacity to predict domain-specific cognitive trajectories, and its convergence with imaging biomarkers.
RESULTS: EOAD participants displayed higher cognitive dispersion than EOnonAD participants, and associations with EOAD-specific biomarkers. Additionally, cognitive dispersion was associated with 12-month reliable change across several cognitive domains.
DISCUSSION: These preliminary results examine cognitive dispersion in sporadic EOAD. When used with baseline cognitive performance, cognitive dispersion measures may enrich future clinical trials in EOAD by enhancing treatment monitoring over time.